These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

480 related articles for article (PubMed ID: 29873072)

  • 1. Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trials.
    Jones J; Mato A; Coutre S; Byrd JC; Furman RR; Hillmen P; Osterborg A; Tam C; Stilgenbauer S; Wierda WG; Heerema NA; Eckert K; Clow F; Zhou C; Chu AD; James DF; O'Brien SM
    Br J Haematol; 2018 Aug; 182(4):504-512. PubMed ID: 29873072
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience.
    O'Brien S; Furman RR; Coutre S; Flinn IW; Burger JA; Blum K; Sharman J; Wierda W; Jones J; Zhao W; Heerema NA; Johnson AJ; Luan Y; James DF; Chu AD; Byrd JC
    Blood; 2018 Apr; 131(17):1910-1919. PubMed ID: 29437592
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study.
    Burger JA; Keating MJ; Wierda WG; Hartmann E; Hoellenriegel J; Rosin NY; de Weerdt I; Jeyakumar G; Ferrajoli A; Cardenas-Turanzas M; Lerner S; Jorgensen JL; Nogueras-González GM; Zacharian G; Huang X; Kantarjian H; Garg N; Rosenwald A; O'Brien S
    Lancet Oncol; 2014 Sep; 15(10):1090-9. PubMed ID: 25150798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study.
    O'Brien S; Jones JA; Coutre SE; Mato AR; Hillmen P; Tam C; Österborg A; Siddiqi T; Thirman MJ; Furman RR; Ilhan O; Keating MJ; Call TG; Brown JR; Stevens-Brogan M; Li Y; Clow F; James DF; Chu AD; Hallek M; Stilgenbauer S
    Lancet Oncol; 2016 Oct; 17(10):1409-1418. PubMed ID: 27637985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens.
    Thompson PA; O'Brien SM; Wierda WG; Ferrajoli A; Stingo F; Smith SC; Burger JA; Estrov Z; Jain N; Kantarjian HM; Keating MJ
    Cancer; 2015 Oct; 121(20):3612-21. PubMed ID: 26193999
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma.
    Munir T; Brown JR; O'Brien S; Barrientos JC; Barr PM; Reddy NM; Coutre S; Tam CS; Mulligan SP; Jaeger U; Kipps TJ; Moreno C; Montillo M; Burger JA; Byrd JC; Hillmen P; Dai S; Szoke A; Dean JP; Woyach JA
    Am J Hematol; 2019 Dec; 94(12):1353-1363. PubMed ID: 31512258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study.
    Byrd JC; Furman RR; Coutre SE; Flinn IW; Burger JA; Blum K; Sharman JP; Wierda W; Zhao W; Heerema NA; Luan Y; Liu EA; Dean JP; O'Brien S
    Clin Cancer Res; 2020 Aug; 26(15):3918-3927. PubMed ID: 32209572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.
    Chanan-Khan A; Cramer P; Demirkan F; Fraser G; Silva RS; Grosicki S; Pristupa A; Janssens A; Mayer J; Bartlett NL; Dilhuydy MS; Pylypenko H; Loscertales J; Avigdor A; Rule S; Villa D; Samoilova O; Panagiotidis P; Goy A; Mato A; Pavlovsky MA; Karlsson C; Mahler M; Salman M; Sun S; Phelps C; Balasubramanian S; Howes A; Hallek M;
    Lancet Oncol; 2016 Feb; 17(2):200-211. PubMed ID: 26655421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes with ibrutinib by line of therapy and post-ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis.
    O'Brien SM; Byrd JC; Hillmen P; Coutre S; Brown JR; Barr PM; Barrientos JC; Devereux S; Robak T; Reddy NM; Kipps TJ; Tedeschi A; Cymbalista F; Ghia P; Chang S; Ninomoto J; James DF; Burger JA
    Am J Hematol; 2019 May; 94(5):554-562. PubMed ID: 30767298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
    Coutré SE; Furman RR; Flinn IW; Burger JA; Blum K; Sharman J; Jones J; Wierda W; Zhao W; Heerema NA; Johnson AJ; Tran A; Zhou C; Bilotti E; James DF; Byrd JC; O'Brien S
    Clin Cancer Res; 2017 Mar; 23(5):1149-1155. PubMed ID: 28073846
    [No Abstract]   [Full Text] [Related]  

  • 11. Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group.
    Winqvist M; Asklid A; Andersson PO; Karlsson K; Karlsson C; Lauri B; Lundin J; Mattsson M; Norin S; Sandstedt A; Hansson L; Österborg A
    Haematologica; 2016 Dec; 101(12):1573-1580. PubMed ID: 27198718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Descriptive analysis of dosing and outcomes for patients with ibrutinib-treated relapsed or refractory chronic lymphocytic leukemia in a Canadian centre.
    Uminski K; Brown K; Bucher O; Hibbert I; Dhaliwal DH; Johnston JB; Geirnaert M; Dawe DE; Banerji V
    Curr Oncol; 2019 Oct; 26(5):e610-e617. PubMed ID: 31708654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia.
    Kipps TJ; Fraser G; Coutre SE; Brown JR; Barrientos JC; Barr PM; Byrd JC; O'Brien SM; Dilhuydy MS; Hillmen P; Jaeger U; Moreno C; Cramer P; Stilgenbauer S; Chanan-Khan AA; Mahler M; Salman M; Eckert K; Solman IG; Balasubramanian S; Cheng M; Londhe A; Ninomoto J; Howes A; James DF; Hallek M
    Clin Lymphoma Myeloma Leuk; 2019 Nov; 19(11):715-722.e6. PubMed ID: 31447270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ibrutinib versus rituximab in relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma: a randomized, open-label phase 3 study.
    Huang X; Qiu L; Jin J; Zhou D; Chen X; Hou M; Hu J; Hu Y; Ke X; Li J; Liang Y; Liu T; Lv Y; Ren H; Sun A; Wang J; Zhao C; Salman M; Sun S; Howes A; Wang J; Wu P; Li J
    Cancer Med; 2018 Apr; 7(4):1043-1055. PubMed ID: 29533000
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ibrutinib rash in a patient with 17p del chronic lymphocytic leukemia.
    Mannis G; Wu D; Dea T; Mauro T; Hsu G
    Am J Hematol; 2015 Feb; 90(2):179. PubMed ID: 24890909
    [No Abstract]   [Full Text] [Related]  

  • 16. Obinutuzumab and ibrutinib induction therapy followed by a minimal residual disease-driven strategy in patients with chronic lymphocytic leukaemia (ICLL07 FILO): a single-arm, multicentre, phase 2 trial.
    Michallet AS; Dilhuydy MS; Subtil F; Rouille V; Mahe B; Laribi K; Villemagne B; Salles G; Tournilhac O; Delmer A; Portois C; Pegourie B; Leblond V; Tomowiak C; de Guibert S; Orsini F; Banos A; Carassou P; Cartron G; Fornecker LM; Ysebaert L; Dartigeas C; Truchan Graczyk M; Vilque JP; Aurran T; Cymbalista F; Lepretre S; Lévy V; Nguyen-Khac F; Le Garff-Tavernier M; Aanei C; Ticchioni M; Letestu R; Feugier P
    Lancet Haematol; 2019 Sep; 6(9):e470-e479. PubMed ID: 31324600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ibrutinib: a review of its use in patients with mantle cell lymphoma or chronic lymphocytic leukaemia.
    Kim ES; Dhillon S
    Drugs; 2015 May; 75(7):769-76. PubMed ID: 25802231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL.
    Flinn IW; Hillmen P; Montillo M; Nagy Z; Illés Á; Etienne G; Delgado J; Kuss BJ; Tam CS; Gasztonyi Z; Offner F; Lunin S; Bosch F; Davids MS; Lamanna N; Jaeger U; Ghia P; Cymbalista F; Portell CA; Skarbnik AP; Cashen AF; Weaver DT; Kelly VM; Turnbull B; Stilgenbauer S
    Blood; 2018 Dec; 132(23):2446-2455. PubMed ID: 30287523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib.
    Byrd JC; Furman RR; Coutre SE; Burger JA; Blum KA; Coleman M; Wierda WG; Jones JA; Zhao W; Heerema NA; Johnson AJ; Shaw Y; Bilotti E; Zhou C; James DF; O'Brien S
    Blood; 2015 Apr; 125(16):2497-506. PubMed ID: 25700432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study.
    Stilgenbauer S; Eichhorst B; Schetelig J; Coutre S; Seymour JF; Munir T; Puvvada SD; Wendtner CM; Roberts AW; Jurczak W; Mulligan SP; Böttcher S; Mobasher M; Zhu M; Desai M; Chyla B; Verdugo M; Enschede SH; Cerri E; Humerickhouse R; Gordon G; Hallek M; Wierda WG
    Lancet Oncol; 2016 Jun; 17(6):768-778. PubMed ID: 27178240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.